MWM
REGN icon

Moran Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Moran Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.68M Sell
4,300
-98
-2% -$66.7K 0.07% 281
2026
Q1 		$3.4M Sell
4,398
-202
-4% -$155K 0.1% 249
2025
Q4 		$3.55M Buy
4,600
+99
+2% +$67.2K 0.11% 234
2025
Q3 		$2.53M Sell
4,501
-89
-2% -$50.3K 0.08% 261
2025
Q2 		$2.41M Sell
4,590
-15,211
-77% -$8.49M 0.07% 268
2025
Q1 		$12.6M Buy
19,801
+123
+0.6% +$84.6K 0.42% 78
2024
Q4 		$14M Sell
19,678
-2,538
-11% -$2.13M 0.45% 80
2024
Q3 		$23.4M Buy
22,216
+2,572
+13% +$2.86M 0.72% 36
2024
Q2 		$20.6M Sell
19,644
-450
-2% -$436K 0.68% 39
2024
Q1 		$19.3M Sell
20,094
-427
-2% -$406K 0.63% 47
2023
Q4 		$18M Sell
20,521
-7
-0% -$5.76K 0.64% 44
2023
Q3 		$16.9M Sell
20,528
-312
-1% -$245K 0.65% 47
2023
Q2 		$15M Sell
20,840
-745
-3% -$574K 0.56% 66
2023
Q1 		$17.7M Sell
21,585
-401
-2% -$302K 0.67% 48
2022
Q4 		$15.9M Buy
+21,986
New +$16.2M 0.6% 49

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Moran Wealth Management's REGN Position: Q2 2026 in Review

Moran Wealth Management reduced its Regeneron Pharmaceuticals (REGN) stake by 2.2% in Q2 2026, selling an estimated $66.7K and leaving 4,300 shares worth $2.68M. The position accounts for 0.07% of the portfolio, ranked #281.

Moran Wealth Management first reported a position in REGN in Q4 2022 and has held it in 15 quarters since. The position peaked at $23.4M in Q3 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Moran Wealth Management held 4,300 shares of Regeneron Pharmaceuticals worth $2.68M as of Q2 2026.
  • Moran Wealth Management sold 98 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $66.7K.
  • Regeneron Pharmaceuticals made up 0.07% of Moran Wealth Management's portfolio in Q2 2026, its #281 holding.
  • Moran Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
  • Moran Wealth Management's Regeneron Pharmaceuticals position peaked at $23.4M in Q3 2024.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Moran Wealth Management's 13F filing for Q2 2026, filed 5 Aug 2026.